New Maryland Federal Court Opinion in Humira Lawsuits

Many product liability cases have a medical malpractice component to them. Certainly, in the mass tort world, the da Vinci robotic surgery claims come to mind.  In those cases, patients often blame the manufacturer of the robot and the doctor who performed the operation.  The question in these cases is whether jurisdiction for the claim is in state court or federal court, assuming the plaintiff prefers state court as we often do.

In Larson v. Abbott Laboratories, a new federal court decision in Baltimore, Maryland, the plaintiff, who was an HIV-positive space engineer, alleged that the prescription drug Humira caused him an infection that left him with permanent brain damage.

So we have real stakes for everyone.  A big-selling pharmaceutical drug – with billions of dollars in sales a year – that is on the verge of being the subject of a big-time mass tort and a plaintiff who has a brain injury that could lead to a substantial jury award.  So the stakes are high.  (The Humira claims are rarely involving HIV patients and infections, to be precise.  But the point is a large verdict, and Humira will set off the Pavlovian dogs.)

Plaintiff was prescribed Humira for psoriasis, an annoying skin condition that causes severe itching and even red scales.  His claim is that if you have HIV, you are at grave risk for a life-threatening infection.  He alleges Abbott should have told him and his doctor that the drug does this.  He also alleges, partly in the alternative, although they are not mutually exclusive, that the doctors at Union Memorial and Annapolis Infection Disease Associates should have known this.

Abbott sought to transfer the case to a Maryland federal court.  Based on these facts, I know it sounds illogical, but these drug companies are desperate to get into federal court, so they flip every possible stone.

Here, they push two big stones.  First, they federally question jurisdiction under 28 U.S.C. § 1331  because Plaintiff alleged Abbott should have considered HIV-positive patients in clinical trials and warn about it, so that involves the ” interpretation and application of a wide range of important federal statutes and rules.”

This is silly, and Judge Ellen Lipton Hollander almost comes out and says so.

I have searched the Complaint in vain for the assaults on federal regulations described by the Pharmaceutical Defendants. In the Complaint, Ms. Larson does not question Abbott’s compliance with federal regulations or challenge the wisdom of those regulations. Although the Complaint alleges that Abbott’s clinical trials “did not include [HIV+] individuals,” id. ¶ 13, it does not allege that the omission of HIV+ patients was contrary to federal law.

On diversity, they argued what they always spit out:  fraudulent joinder.  Actually, technically here the argument was that doctrine’s half-sister was a fraudulent misjoinder.  Some have applied this doctrine but certainly not all courts when a plaintiff includes claims against some defendants that could be proved but have no real connection to the claims against other defendants in the same action.  These claims have to be found to be tossed in just to create diversity.

There is a big question as to whether this is a doctrine that courts should apply in the first place.  Judge Hollander steers clear of this controversy:

Fortunately, I need not enter this doctrinal thicket. Even if I adopted the fraudulent misjoinder doctrine despite its flaws, applying it to sever the claims in this case would turn it entirely on its head.

This is a really good opinion.  I posted the link above.  If you ever have a controversy about whether state or federal court should have jurisdiction in your case, you should read this opinion.

Contact Information